Devicemaker Consort buys into the CDMO space with Aesica deal

The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.